Insiders sold more than 15,000 shares of company stock on Tuesday.
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Dyne Therapeutics, Inc. (DYN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 84% in Dyne Therapeutics, Inc. (DYN). While the effectiveness of this highly sought-after metric is questionable,...
Dyne Therapeutics, Inc. (DYN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...
The mean of analysts' price targets for Dyne Therapeutics, Inc. (DYN) points to a 141% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...
DINO, DYN, and DLNG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 18, 2022.